Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Anti-CD19 CAR-T Cells in Relapsed/Refractory Lymphoid Malignancies
NCT04732845Phase 1Active, not recruiting
- Start
- Apr 2021
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD19 CAR-T cells in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) (2 arms). Primary endpoint: Recommended Phase II Dose at 24 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04732845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732845.